87488957 - OXFORD BIOMEDICA

Information

• Trademark
• 87488957

• Source

• Serial Number

  87488957

• Registration Number

  5451207

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  June 14, 2017
  7 years ago

• Registration Date

  April 24, 2018
  6 years ago

• Transaction Date

  October 18, 2024
  a month ago

• Status Date

  April 24, 2018
  6 years ago

• Published for Opposition Date

  November 07, 2017
  7 years ago

• Location Date

  April 24, 2018
  6 years ago

• Status Code

  700

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  VAGHANI, MAYUR

• Attorney Docket Number

  KILB.00031.T

  Attorney Name

  Roberta S. Bren

  Law Office Assigned Location Code

  N60

• Owners

  • OXFORD BIOMEDICA (UK) LIMITED

Case File Statements

• GS0051: Clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing retroviral vector preparations and/or nucleic acid suitable for gene therapy; retroviral vector preparations for use in gene therapy; pharmaceutical preparations containing a retroviral vector delivering genes to cells for use in the treatment of viral and bacterial infections, cancer, HIV and AIDS, neurodegenerative diseases, diseases of the eye, leukemia and bodily conditions associated with impaired immunosystems; Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals; small molecules, vaccines, biologics, enzymes and enzyme preparations all for medical treatment purposes; pharmaceuticals for medical purposes for the delivery of genes to cells; viral, retroviral and non-viral vectors, all for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes; pre-filled vials for medical purposes and for pharmaceutical and biochemical preparations, for use in gene therapy and for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders
• GS0011: Chemical compositions containing nucleic acids for use in the manufacture of pharmaceuticals and retroviral vector preparations; Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicals, namely, precursors for in vitro genetic engineering use; polypeptides for in vitro research use, monoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research use, viruses for laboratory and scientific research use, cell cultures for laboratory and scientific research use, plasmids and cultures of micro-organisms for laboratory and scientific research use, nucleic acid sequences for laboratory and scientific research use, cloning vehicles in the nature of plasmids, microbes and chemical reagents for DNA cloning for laboratory and scientific research use, chemicals for laboratory, scientific and biotechnology research and development and recombinant nucleic acid variations thereof for laboratory and scientific research use, namely, in vitro and in vivo use
• GS0441: Medical services; advisory services relating to vaccination regimes; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders and contraceptives
• DS0000: "OXFORD"
• GS0421: Scientific, pharmaceutical and medical research and development; genetic engineering services, biotechnology services, namely, research and development for new products in the field of biotechnology, advisory services relating to gene therapy products and clinical trials, conducting clinical trials

Case File Event Statements

• 9/18/2017 - 7 years ago

  6 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 6/17/2017 - 7 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 6/21/2017 - 7 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 9/13/2017 - 7 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 9/18/2017 - 7 years ago

  4 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 9/18/2017 - 7 years ago

  7 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 9/18/2017 - 7 years ago

  5 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 3/20/2018 - 6 years ago

  17 - 1(B) BASIS DELETED; PROCEED TO REGISTRATION Type: DP1B

• 9/18/2017 - 7 years ago

  8 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 10/1/2017 - 7 years ago

  9 - ASSIGNED TO LIE Type: ALIE

• 10/18/2017 - 7 years ago

  10 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 11/7/2017 - 7 years ago

  11 - PUBLISHED FOR OPPOSITION Type: PUBO

• 11/7/2017 - 7 years ago

  12 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 1/2/2018 - 6 years ago

  13 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 3/6/2018 - 6 years ago

  14 - TEAS DELETE 1(B) BASIS RECEIVED Type: D1BR

• 3/6/2018 - 6 years ago

  16 - NOTICE OF ALLOWANCE CANCELLED Type: IUCN

• 3/20/2018 - 6 years ago

  15 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU

• 4/24/2023 - a year ago

  21 - COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Type: REM1

• 10/17/2024 - a month ago

  22 - TEAS SECTION 8 & 15 RECEIVED Type: E815

• 6/8/2018 - 6 years ago

  20 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN

• 4/24/2018 - 6 years ago

  18 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 6/8/2018 - 6 years ago

  19 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR